RU97108591A - NUCLEOSIDES WITH MODIFIED SUGARS AND THEIR APPLICATION FOR THE SYNTHESIS OF OLIGONUCLEOTIDE - Google Patents
NUCLEOSIDES WITH MODIFIED SUGARS AND THEIR APPLICATION FOR THE SYNTHESIS OF OLIGONUCLEOTIDEInfo
- Publication number
- RU97108591A RU97108591A RU97108591/04A RU97108591A RU97108591A RU 97108591 A RU97108591 A RU 97108591A RU 97108591/04 A RU97108591/04 A RU 97108591/04A RU 97108591 A RU97108591 A RU 97108591A RU 97108591 A RU97108591 A RU 97108591A
- Authority
- RU
- Russia
- Prior art keywords
- substituted
- group
- aralkyl
- aryl
- alkyl
- Prior art date
Links
- 229920000272 Oligonucleotide Polymers 0.000 title claims 13
- 239000002777 nucleoside Substances 0.000 title claims 7
- 230000015572 biosynthetic process Effects 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
- 230000002194 synthesizing Effects 0.000 title 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 38
- 125000000547 substituted alkyl group Chemical group 0.000 claims 25
- 125000003107 substituted aryl group Chemical group 0.000 claims 23
- 125000000217 alkyl group Chemical group 0.000 claims 18
- 150000001875 compounds Chemical class 0.000 claims 15
- 125000005418 aryl aryl group Chemical group 0.000 claims 10
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 6
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 5
- -1 aralkoxy Chemical group 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 229910052794 bromium Inorganic materials 0.000 claims 3
- 229910052801 chlorine Inorganic materials 0.000 claims 3
- 229910052731 fluorine Inorganic materials 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 229910052740 iodine Inorganic materials 0.000 claims 3
- 101700080605 NUC1 Proteins 0.000 claims 2
- 230000000903 blocking Effects 0.000 claims 2
- 125000000524 functional group Chemical group 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 239000000138 intercalating agent Substances 0.000 claims 2
- 101700006494 nucA Proteins 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 239000004971 Cross linker Substances 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 239000003431 cross linking reagent Substances 0.000 claims 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000003835 nucleoside group Chemical group 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000003367 polycyclic group Chemical group 0.000 claims 1
Claims (27)
где B представляет собой нуклеозидное основание;
любая алкильная составляющая представляет собой линейный или разветвленный, насыщенный или ненасыщенный C1-C10;
любая арильная составляющая представляет собой фенил, полициклическое кольцо или гетероцикл;
R2 выбран из группы, состоящей из H, OH, алкокси, аралкокси и арилокси;
X представляет собой S, NH, O или CH2;
(I), где R3 и R5 независимо выбраны из группы, состоящей из OH, OCEPA и гидроксилблокирующей группы;
(А) где X представляет собой CH2, S или NH;
независимо выбраны из группы, состоящей из H, CN, N3, NO2, CF3, алкила, замещенного алкила, аралкила, замещенного аралкила, арила и замещенного арила при условии, что не могут все быть H одновременно;
замещенная составляющая по меньшей мере одного замещенного аралкила и замещенного арила из выбрана из группы, состоящей из CN, NO2, N3, CF3, NH2, NR2, OH, OR, SH, COOH, COOR, SO3R, F, Cl, Br и I, где R выбран из группы, состоящей из H, алкила, аралкила, арила, Ac, CF3CO, Ts;
(Б) где X представляет собой O;
выбран из группы, состоящей из N3, NO2, CF3, алкила, замещенного алкила, аралкила, замещенного аралкила, арила и замещенного арила, где
замещенная составляющая по меньшей мере одного замещенного алкила, замещенного аралкила и замещенного арила выбрана из группы, состоящей из NO2, N3, CF3, SH, SR, COOH, COOR, SO3H, SO3R, F, Cl, Br и I, где R выбран из группы, состоящей из низшего алкила, аралкила и арила; и
все являются H;
(В) где X представляет собой O;
выбран из группы, состоящей из CN, N3, NO2, CF3, замещенного алкила, аралкила, замещенного аралкила, арила и замещенного арила, где
замещенная составляющая по меньшей мере одного замещенного алкила, замещенного аралкила и замещенного арила выбрана из группы, состоящей из CN, N3, CF3, NH2, NR2, OR, SH, SR, COOH, COOR, SO3R, F, Cl, Br и I, где R выбран из группы, состоящей из низшего алкила, аралкила и арила; и
все являются H;
(II), где X = O;
один из радикалов R3 и R5 представляет собой межнуклеотидную связь, а другой выбран из группы, состоящей из OH, межнуклеотидной связи и гидроксилблокирующей группы;
обозначает H; и
два радикала из обозначают H, а третий модифицирован, как указано ниже:
(А) выбран из группы, состоящей из замещенного алкила, аралкила, замещенного аралкила, арила и замещенного арила, а
замещенная составляющая замещенного алкила является иной, чем OH;
(Б) выбран из группы, состоящей из замещенного алкила, замещенного аралкила, арила и замещенного арила, радикала с высокой электроотрицательностью, CF3 и NO2, причем не содержит метки; и
замещенная составляющая замещенного алкила и замещенного аралкила является иной, чем OH, CHO, SH, NH2, COOH и NHC(O)CF3; и
(В) когда R5 обозначает межнуклеотидную связь;
выбран из группы, состоящей из замещенного алкила, аралкила, замещенного аралкила, арила и замещенного арила, а
замещенная составляющая замещенного алкила является иной, чем NH2 и эпоксиэтил.1. The compound having the structure
where B is a nucleoside base;
any alkyl component represents linear or branched, saturated or unsaturated C 1 -C 10 ;
any aryl component is phenyl, a polycyclic ring or a heterocycle;
R 2 is selected from the group consisting of H, OH, alkoxy, aralkoxy, and aryloxy;
X is S, NH, O or CH 2 ;
(I), where R 3 and R 5 are independently selected from the group consisting of OH, OCEPA and a hydroxyl blocking group;
(A) where X is CH 2 , S or NH;
are independently selected from the group consisting of H, CN, N 3 , NO 2 , CF 3 , alkyl, substituted alkyl, aralkyl, substituted aralkyl, aryl, and substituted aryl, provided that cannot all be H at the same time;
substituted component of at least one substituted aralkyl and substituted aryl of selected from the group consisting of CN, NO 2 , N 3 , CF 3 , NH 2 , NR 2 , OH, OR, SH, COOH, COOR, SO 3 R, F, Cl, Br and I, where R is selected from the group consisting of H, alkyl, aralkyl, aryl, Ac, CF 3 CO, Ts;
(B) where X is O;
selected from the group consisting of N 3 , NO 2 , CF 3 , alkyl, substituted alkyl, aralkyl, substituted aralkyl, aryl and substituted aryl, where
a substituted component of at least one substituted alkyl, substituted aralkyl, and substituted aryl is selected from the group consisting of NO 2 , N 3 , CF 3 , SH, SR, COOH, COOR, SO 3 H, SO 3 R, F, Cl, Br and I, wherein R is selected from the group consisting of lower alkyl, aralkyl, and aryl; and
all are H;
(B) where X is O;
is selected from the group consisting of CN, N 3 , NO 2 , CF 3 , substituted alkyl, aralkyl, substituted aralkyl, aryl and substituted aryl, where
the substituted component of at least one substituted alkyl, substituted aralkyl and substituted aryl is selected from the group consisting of CN, N 3 , CF 3 , NH 2 , NR 2 , OR, SH, SR, COOH, COOR, SO 3 R, F, Cl, Br and I, where R is selected from the group consisting of lower alkyl, aralkyl and aryl; and
all are H;
(Ii) where X = O;
one of the radicals R 3 and R 5 is an internucleotide bond, and the other is selected from the group consisting of OH, the internucleotide bond and a hydroxyl blocking group;
is H; and
two radicals from denote H, and the third modified, as follows:
(BUT) is selected from the group consisting of substituted alkyl, aralkyl, substituted aralkyl, aryl and substituted aryl, and
the substituted component of the substituted alkyl is other than OH;
(B) is selected from the group consisting of substituted alkyl, substituted aralkyl, aryl and substituted aryl, a high electronegativity radical, CF 3 and NO 2 , and does not contain a label; and
the substituted component of the substituted alkyl and substituted aralkyl is other than OH, CHO, SH, NH 2 , COOH and NHC (O) CF 3 ; and
(B) when R 5 is internucleotide bond;
is selected from the group consisting of substituted alkyl, aralkyl, substituted aralkyl, aryl and substituted aryl, and
the substituted component of the substituted alkyl is other than NH 2 and epoxyethyl.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/333,545 | 1994-11-02 | ||
US08/333,545 US5681940A (en) | 1994-11-02 | 1994-11-02 | Sugar modified nucleosides and oligonucleotides |
PCT/US1995/014600 WO1996014329A1 (en) | 1994-11-02 | 1995-11-02 | Sugar modified nucleosides and their use for synthesis of oligonucleotides |
Publications (2)
Publication Number | Publication Date |
---|---|
RU97108591A true RU97108591A (en) | 1999-05-20 |
RU2145964C1 RU2145964C1 (en) | 2000-02-27 |
Family
ID=23303253
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU97108591/04A RU2145964C1 (en) | 1994-11-02 | 1995-11-02 | Nucleosides with modified sugars and oligonucleotides |
Country Status (17)
Country | Link |
---|---|
US (3) | US5681940A (en) |
EP (1) | EP0789706A4 (en) |
JP (1) | JP3633626B2 (en) |
KR (1) | KR100274331B1 (en) |
CN (1) | CN1122040C (en) |
AU (1) | AU690394B2 (en) |
CA (2) | CA2202280C (en) |
CZ (1) | CZ293731B6 (en) |
HK (1) | HK1007881A1 (en) |
HU (1) | HUT77516A (en) |
MX (1) | MX9703192A (en) |
PL (1) | PL184378B1 (en) |
RU (1) | RU2145964C1 (en) |
SI (1) | SI9520113A (en) |
SK (1) | SK54897A3 (en) |
UA (1) | UA45362C2 (en) |
WO (1) | WO1996014329A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2699985C2 (en) * | 2013-05-01 | 2019-09-11 | Ионис Фармасьютикалз, Инк. | Compositions and methods for modulating expression of apolipoprotein (a) |
RU2712559C2 (en) * | 2013-08-28 | 2020-01-29 | Ионис Фармасьютикалз, Инк. | Modulation of prekallikrein (pkk) expression |
Families Citing this family (111)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6743902B1 (en) * | 1994-11-02 | 2004-06-01 | Valeant Pharmaceuticals International | Sugar modified nucleosides |
EP0747389B1 (en) * | 1994-12-13 | 2003-09-10 | Taiho Pharmaceutical Co., Ltd. | 3'-substituted nucleoside derivatives |
US7812149B2 (en) | 1996-06-06 | 2010-10-12 | Isis Pharmaceuticals, Inc. | 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations |
US20050118605A9 (en) * | 1996-06-06 | 2005-06-02 | Baker Brenda F. | Oligomeric compounds having modified bases for binding to adenine and guanine and their use in gene modulation |
US9096636B2 (en) * | 1996-06-06 | 2015-08-04 | Isis Pharmaceuticals, Inc. | Chimeric oligomeric compounds and their use in gene modulation |
US20040171030A1 (en) * | 1996-06-06 | 2004-09-02 | Baker Brenda F. | Oligomeric compounds having modified bases for binding to cytosine and uracil or thymine and their use in gene modulation |
US20040161777A1 (en) * | 1996-06-06 | 2004-08-19 | Baker Brenda F. | Modified oligonucleotides for use in RNA interference |
US5898031A (en) * | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
US20040161844A1 (en) * | 1996-06-06 | 2004-08-19 | Baker Brenda F. | Sugar and backbone-surrogate-containing oligomeric compounds and compositions for use in gene modulation |
US20040171032A1 (en) * | 1996-06-06 | 2004-09-02 | Baker Brenda F. | Non-phosphorous-linked oligomeric compounds and their use in gene modulation |
US6210707B1 (en) * | 1996-11-12 | 2001-04-03 | The Regents Of The University Of California | Methods of forming protein-linked lipidic microparticles, and compositions thereof |
US6127533A (en) | 1997-02-14 | 2000-10-03 | Isis Pharmaceuticals, Inc. | 2'-O-aminooxy-modified oligonucleotides |
US6576752B1 (en) | 1997-02-14 | 2003-06-10 | Isis Pharmaceuticals, Inc. | Aminooxy functionalized oligomers |
US6172209B1 (en) | 1997-02-14 | 2001-01-09 | Isis Pharmaceuticals Inc. | Aminooxy-modified oligonucleotides and methods for making same |
US20050282198A1 (en) * | 1997-05-29 | 2005-12-22 | Interleukin Genetics, Inc. | Diagnostics and therapeutics for diseases associated with an IL-1 inflammatory haplotype |
GB9711040D0 (en) * | 1997-05-29 | 1997-07-23 | Duff Gordon W | Prediction of inflammatory disease |
DE04020014T1 (en) | 1997-09-12 | 2006-01-26 | Exiqon A/S | Bi-cyclic - nucleoside, nucleotide and oligonucleotide analogs |
CA2370478A1 (en) | 1999-03-24 | 2000-09-28 | Serge L. Beaucage | N-acylphosphoramidites and their use in oligonucleotide synthesis |
US6900186B1 (en) * | 1999-06-21 | 2005-05-31 | Murdock Children's Research Institute | Method for the prophylaxis and/or treatment of medical disorders |
US20020142982A1 (en) * | 1999-09-02 | 2002-10-03 | Timothy Hla | Method for regulating angiogenesis |
CA2410263C (en) * | 2000-05-26 | 2014-02-04 | Gencell S.A. | Purification of a triple helix formation with an immobilized oligonucleotide |
GB0013276D0 (en) * | 2000-06-01 | 2000-07-26 | Amersham Pharm Biotech Uk Ltd | Nucleotide analogues |
US6936702B2 (en) | 2000-06-07 | 2005-08-30 | Li-Cor, Inc. | Charge-switch nucleotides |
US6869764B2 (en) | 2000-06-07 | 2005-03-22 | L--Cor, Inc. | Nucleic acid sequencing using charge-switch nucleotides |
EP1287154A4 (en) | 2000-06-07 | 2010-12-15 | Pacific Biosciences California | Charge-switch nucleotides |
ES2299561T3 (en) * | 2001-01-26 | 2008-06-01 | Btg International Limited | BENCILAMINE ANALOG. |
AU2002258997A1 (en) * | 2001-04-24 | 2002-11-05 | Li-Cor, Inc. | Polymerases with charge-switch activity and methods of generating such polymerases |
US7118907B2 (en) * | 2001-06-06 | 2006-10-10 | Li-Cor, Inc. | Single molecule detection systems and methods |
GB0114286D0 (en) * | 2001-06-12 | 2001-08-01 | Hoffmann La Roche | Nucleoside Derivatives |
WO2003026675A1 (en) * | 2001-09-28 | 2003-04-03 | Idenix (Cayman) Limited | Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside |
US7138376B2 (en) * | 2001-09-28 | 2006-11-21 | Idenix Pharmaceuticals, Inc. | Methods and compositions for treating hepatitis C virus using 4'-modified nucleosides |
US20080311581A1 (en) * | 2001-11-19 | 2008-12-18 | David Wyllie | Functional polymorphisms of the interleukin-1 locus affecting transcription and susceptibility to inflammatory and infectious diseases |
WO2003048179A2 (en) * | 2001-12-03 | 2003-06-12 | The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services | Thermolabile hydroxyl protecting groups and methods of use |
GB0129012D0 (en) | 2001-12-04 | 2002-01-23 | Solexa Ltd | Labelled nucleotides |
US11008359B2 (en) | 2002-08-23 | 2021-05-18 | Illumina Cambridge Limited | Labelled nucleotides |
WO2004018497A2 (en) | 2002-08-23 | 2004-03-04 | Solexa Limited | Modified nucleotides for polynucleotide sequencing |
US7414116B2 (en) | 2002-08-23 | 2008-08-19 | Illumina Cambridge Limited | Labelled nucleotides |
WO2004042029A2 (en) * | 2002-11-05 | 2004-05-21 | Isis Pharmaceuticals, Inc. | Oligomers comprising modified bases for binding cytosine and uracil or thymine and their use |
US9150606B2 (en) | 2002-11-05 | 2015-10-06 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2'-modified nucleosides for use in gene modulation |
US9150605B2 (en) * | 2002-11-05 | 2015-10-06 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
EP1562971B1 (en) * | 2002-11-05 | 2014-02-12 | Isis Pharmaceuticals, Inc. | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
JP2006516099A (en) * | 2002-12-23 | 2006-06-22 | ダイナバックス テクノロジーズ コーポレイション | Branched immunomodulatory compounds and methods of using the compounds |
US8569474B2 (en) | 2004-03-09 | 2013-10-29 | Isis Pharmaceuticals, Inc. | Double stranded constructs comprising one or more short strands hybridized to a longer strand |
US8394947B2 (en) | 2004-06-03 | 2013-03-12 | Isis Pharmaceuticals, Inc. | Positionally modified siRNA constructs |
US7884086B2 (en) | 2004-09-08 | 2011-02-08 | Isis Pharmaceuticals, Inc. | Conjugates for use in hepatocyte free uptake assays |
WO2006065751A2 (en) * | 2004-12-13 | 2006-06-22 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Cpg oligonucleotide prodrugs, compositions thereof and associated therapeutic methods |
PT1888748E (en) * | 2005-05-25 | 2013-12-02 | Tina Holding Aps | Stable and selective formation of hoogsteen-type triplexes and duplexes using twisted intercalating nucleic acids (tina) and process for the preparation of tina |
WO2007125173A2 (en) | 2006-05-03 | 2007-11-08 | Baltic Technology Development, Ltd. | Antisense agents combining strongly bound base - modified oligonucleotide and artificial nuclease |
JP4823310B2 (en) * | 2006-06-06 | 2011-11-24 | パナソニック株式会社 | Nucleotide chain modification method |
SI2494993T1 (en) | 2007-05-04 | 2019-01-31 | Marina Biotech, Inc. | Amino acid lipids and uses thereof |
US10131904B2 (en) | 2008-02-11 | 2018-11-20 | Rxi Pharmaceuticals Corporation | Modified RNAi polynucleotides and uses thereof |
US20100015708A1 (en) * | 2008-06-18 | 2010-01-21 | Mdrna, Inc. | Ribonucleic acids with non-standard bases and uses thereof |
WO2010008582A2 (en) | 2008-07-18 | 2010-01-21 | Rxi Pharmaceuticals Corporation | Phagocytic cell drug delivery system |
CA2746527A1 (en) | 2008-09-22 | 2010-03-25 | Rxi Pharmaceuticals Corporation | Rna interference in skin indications |
WO2010045512A2 (en) | 2008-10-16 | 2010-04-22 | Mdrna , Inc. | Processes and compositions for liposomal and efficient delivery of gene silencing therapeutics |
AU2009308217B2 (en) | 2008-10-24 | 2016-01-21 | Ionis Pharmaceuticals, Inc. | 5' and 2' bis-substituted nucleosides and oligomeric compounds prepared therefrom |
EP2358398A2 (en) * | 2008-10-24 | 2011-08-24 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and methods |
WO2010059226A2 (en) | 2008-11-19 | 2010-05-27 | Rxi Pharmaceuticals Corporation | Inhibition of map4k4 through rnai |
BRPI0923225A2 (en) | 2008-12-02 | 2016-10-04 | Chiralgen Ltd | Phosphorus-modified nucleic acid synthesis method |
US9493774B2 (en) | 2009-01-05 | 2016-11-15 | Rxi Pharmaceuticals Corporation | Inhibition of PCSK9 through RNAi |
WO2010090762A1 (en) | 2009-02-04 | 2010-08-12 | Rxi Pharmaceuticals Corporation | Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
CN102421293A (en) * | 2009-03-20 | 2012-04-18 | 艾丽奥斯生物制药有限公司 | Substituted nucleoside and nucleotide analogs |
RU2612521C2 (en) | 2009-07-06 | 2017-03-09 | Онтории, Инк. | Novel prodrugs of nucleic acids and their application methods |
US9340786B2 (en) | 2010-03-24 | 2016-05-17 | Rxi Pharmaceuticals Corporation | RNA interference in dermal and fibrotic indications |
EP2550000A4 (en) | 2010-03-24 | 2014-03-26 | Advirna Inc | Reduced size self-delivering rnai compounds |
CA2794187C (en) | 2010-03-24 | 2020-07-14 | Rxi Pharmaceuticals Corporation | Rna interference in ocular indications |
US9127033B2 (en) | 2010-04-28 | 2015-09-08 | Isis Pharmaceuticals, Inc. | 5′ modified nucleosides and oligomeric compounds prepared therefrom |
JP6005628B2 (en) | 2010-04-28 | 2016-10-12 | アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. | Modified nucleosides, analogs thereof, and oligomeric compounds prepared therefrom |
US8877731B2 (en) | 2010-09-22 | 2014-11-04 | Alios Biopharma, Inc. | Azido nucleosides and nucleotide analogs |
JP6012605B2 (en) | 2010-09-22 | 2016-10-25 | アリオス バイオファーマ インク. | Substituted nucleotide analogs |
US10428019B2 (en) | 2010-09-24 | 2019-10-01 | Wave Life Sciences Ltd. | Chiral auxiliaries |
CN107365339A (en) | 2011-07-19 | 2017-11-21 | 波涛生命科学有限公司 | The method for synthesizing functionalization nucleic acid |
CA2860234A1 (en) | 2011-12-22 | 2013-06-27 | Alios Biopharma, Inc. | Substituted phosphorothioate nucleotide analogs |
SG11201402826YA (en) | 2011-12-22 | 2014-12-30 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
NZ631601A (en) | 2012-03-21 | 2016-06-24 | Alios Biopharma Inc | Solid forms of a thiophosphoramidate nucleotide prodrug |
EP2827876A4 (en) | 2012-03-22 | 2015-10-28 | Alios Biopharma Inc | Pharmaceutical combinations comprising a thionucleotide analog |
JP6246121B2 (en) | 2012-07-13 | 2017-12-13 | 株式会社新日本科学 | Chiral nucleic acid adjuvant |
PL2872147T3 (en) | 2012-07-13 | 2023-09-25 | Wave Life Sciences Ltd. | Method for making chiral oligonucleotides |
EP2872485B1 (en) | 2012-07-13 | 2020-12-16 | Wave Life Sciences Ltd. | Asymmetric auxiliary group |
JP6570447B2 (en) | 2012-10-15 | 2019-09-04 | アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. | Composition for modulating C9ORF72 expression |
WO2014062736A1 (en) | 2012-10-15 | 2014-04-24 | Isis Pharmaceuticals, Inc. | Methods for monitoring c9orf72 expression |
US9725474B2 (en) | 2012-10-31 | 2017-08-08 | Takeda Pharmaceutical Company Limited | Modified nucleic acid |
CA2903095C (en) | 2013-03-15 | 2018-02-13 | Xiaohai Liu | Modified nucleosides or nucleotides |
MX2016004651A (en) | 2013-10-11 | 2016-08-05 | Ionis Pharmaceuticals Inc | Compositions for modulating c9orf72 expression. |
JP6772062B2 (en) | 2013-12-02 | 2020-10-21 | フィオ ファーマシューティカルズ コーポレーションPhio Pharmaceuticals Corp. | Cancer immunotherapy |
WO2015106128A2 (en) * | 2014-01-09 | 2015-07-16 | Alnylam Pharmaceuticals, Inc. | MODIFIED RNAi AGENTS |
JPWO2015108048A1 (en) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | Chiral nucleic acid adjuvant and antitumor agent having antitumor activity |
EP3095460A4 (en) | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent |
WO2015108047A1 (en) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator |
JP6382344B2 (en) | 2014-01-16 | 2018-08-29 | ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. | Chiral design |
US11279934B2 (en) | 2014-04-28 | 2022-03-22 | Phio Pharmaceuticals Corp. | Methods for treating cancer using nucleic acids targeting MDM2 or MYCN |
BR112016022855B1 (en) | 2014-05-01 | 2022-08-02 | Ionis Pharmaceuticals, Inc | COMPOUNDS AND COMPOSITIONS TO MODULATE THE EXPRESSION OF PKK AND ITS USES |
RS59182B1 (en) * | 2014-05-01 | 2019-10-31 | Ionis Pharmaceuticals Inc | Compositions and methods for modulating complement factor b expression |
CN104211741B (en) * | 2014-09-05 | 2017-05-31 | 河南师范大学 | A kind of synthetic method of deuterated nucleoside phosphoramidites monomer |
WO2016037071A2 (en) | 2014-09-05 | 2016-03-10 | Rxi Pharmaceuticals Corporation | Methods for treating aging and skin disorders using nucleic acids targeting tyr or mmp1 |
CN113265404A (en) * | 2015-04-16 | 2021-08-17 | Ionis制药公司 | Compositions for modulating expression of C9ORF72 |
US11001845B2 (en) | 2015-07-06 | 2021-05-11 | Phio Pharmaceuticals Corp. | Nucleic acid molecules targeting superoxide dismutase 1 (SOD1) |
US10808247B2 (en) | 2015-07-06 | 2020-10-20 | Phio Pharmaceuticals Corp. | Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach |
WO2017070151A1 (en) | 2015-10-19 | 2017-04-27 | Rxi Pharmaceuticals Corporation | Reduced size self-delivering nucleic acid compounds targeting long non-coding rna |
WO2017079291A1 (en) | 2015-11-02 | 2017-05-11 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating c90rf72 |
US11643432B2 (en) | 2016-12-16 | 2023-05-09 | National University Corporation Tokai National Higher Education And Research System | Nucleoside derivative and use thereof |
JP7231147B2 (en) * | 2017-06-29 | 2023-03-01 | 国立大学法人東海国立大学機構 | RNA introduction reagent and its use |
JP7173467B2 (en) * | 2017-10-31 | 2022-11-16 | ヤマサ醤油株式会社 | Nucleoside derivative and its use |
EP3770256A4 (en) * | 2018-03-20 | 2021-12-22 | Tokyo Institute of Technology | Antisense oligonucleotide having reduced toxicity |
JP2022522534A (en) | 2019-04-02 | 2022-04-19 | アリゴス セラピューティクス インコーポレイテッド | Compounds that target PRMT5 |
TW202322824A (en) | 2020-02-18 | 2023-06-16 | 美商基利科學股份有限公司 | Antiviral compounds |
TW202245800A (en) | 2020-02-18 | 2022-12-01 | 美商基利科學股份有限公司 | Antiviral compounds |
CN118598916A (en) | 2020-02-18 | 2024-09-06 | 吉利德科学公司 | Antiviral compounds |
WO2022221514A1 (en) | 2021-04-16 | 2022-10-20 | Gilead Sciences, Inc. | Methods of preparing carbanucleosides using amides |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5190969A (en) * | 1988-12-20 | 1993-03-02 | The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services | 2,3-epoxy derivatives as anti retrovital chemotherapeutic agents |
US5378825A (en) * | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
FR2687679B1 (en) * | 1992-02-05 | 1994-10-28 | Centre Nat Rech Scient | OLIGOTHIONUCLEOTIDES. |
JPH08508490A (en) * | 1993-03-31 | 1996-09-10 | スターリング ウィンスロップ インコーポレイティド | Novel 5'-substituted nucleosides and oligomers obtained therefrom |
US5446137B1 (en) * | 1993-12-09 | 1998-10-06 | Behringwerke Ag | Oligonucleotides containing 4'-substituted nucleotides |
-
1994
- 1994-11-02 US US08/333,545 patent/US5681940A/en not_active Expired - Lifetime
-
1995
- 1995-11-02 SK SK548-97A patent/SK54897A3/en unknown
- 1995-11-02 PL PL95319944A patent/PL184378B1/en not_active IP Right Cessation
- 1995-11-02 CA CA002202280A patent/CA2202280C/en not_active Expired - Fee Related
- 1995-11-02 EP EP95939864A patent/EP0789706A4/en not_active Withdrawn
- 1995-11-02 CA CA002307311A patent/CA2307311A1/en not_active Abandoned
- 1995-11-02 WO PCT/US1995/014600 patent/WO1996014329A1/en not_active Application Discontinuation
- 1995-11-02 CN CN95196962A patent/CN1122040C/en not_active Expired - Fee Related
- 1995-11-02 AU AU41525/96A patent/AU690394B2/en not_active Ceased
- 1995-11-02 KR KR1019970702924A patent/KR100274331B1/en not_active IP Right Cessation
- 1995-11-02 RU RU97108591/04A patent/RU2145964C1/en not_active IP Right Cessation
- 1995-11-02 SI SI9520113A patent/SI9520113A/en unknown
- 1995-11-02 US US08/552,363 patent/US5712378A/en not_active Expired - Fee Related
- 1995-11-02 MX MX9703192A patent/MX9703192A/en unknown
- 1995-11-02 HU HU9702445A patent/HUT77516A/en unknown
- 1995-11-02 UA UA97041994A patent/UA45362C2/en unknown
- 1995-11-02 JP JP51551996A patent/JP3633626B2/en not_active Expired - Fee Related
- 1995-11-02 CZ CZ19971291A patent/CZ293731B6/en not_active IP Right Cessation
-
1996
- 1996-12-16 US US08/766,991 patent/US6191266B1/en not_active Expired - Fee Related
-
1998
- 1998-07-09 HK HK98109044A patent/HK1007881A1/en not_active IP Right Cessation
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2699985C2 (en) * | 2013-05-01 | 2019-09-11 | Ионис Фармасьютикалз, Инк. | Compositions and methods for modulating expression of apolipoprotein (a) |
RU2712559C2 (en) * | 2013-08-28 | 2020-01-29 | Ионис Фармасьютикалз, Инк. | Modulation of prekallikrein (pkk) expression |
RU2712559C9 (en) * | 2013-08-28 | 2020-10-08 | Ионис Фармасьютикалз, Инк. | Modulation of prekallikrein (pkk) expression |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU97108591A (en) | NUCLEOSIDES WITH MODIFIED SUGARS AND THEIR APPLICATION FOR THE SYNTHESIS OF OLIGONUCLEOTIDE | |
RU2221798C2 (en) | Imidazonaphthyridines, pharmaceutical composition based on thereof, method for stimulating biosynthesis of cytokine and intermediate compounds | |
SE7610922L (en) | LIGHT PROTECTIVE FOR COSMETIC PURPOSES | |
KR970701708A (en) | 9-Deoxotaxane compounds | |
RU95119429A (en) | ORGANOSILOXANES CONTAINING THEIR COSMETIC COMPOSITIONS AND METHOD FOR PROTECTING SKIN | |
RU95120241A (en) | DERIVATIVES OF DIORGANOSYLOXANES OR TRIORGANOSILANE, LIGHT-PROTECTIVE COSMETIC COMPOSITION ON THEIR BASIS AND METHOD OF PROTECTING THE SKIN | |
RU92004429A (en) | DERIVATIVES 2- (1-PIPERASINIL) -4-PHENYL-CYCLO-ALKANOPYRIDINE | |
ATE92746T1 (en) | POLYETHER IMPRESSION MATERIAL, PROCESS FOR ITS PREPARATION AND ITS USE. | |
ES2194683T3 (en) | NEW SILICATED DERIVATIVES OF N-SUBSTITUTED BENCIMIDAZOL-BENZAZOLES OR BEZOFURANIL-BENZAZOLES FILTERS; PHOTOPROTECTOR COSMETIC COMPOSITIONS CONTAINING AND USING THEM. | |
DE59308843D1 (en) | Polysiloxane-containing binders, their preparation, coating compositions containing them and their use | |
DE69818042D1 (en) | LIQUID BENZISOCHINOLINE DERIVATIVES | |
RU2001135740A (en) | Composition for use in paints | |
RU92016591A (en) | DERIVATIVES OF PYRIMIDINE NUCLEOSIDE | |
RU96105034A (en) | CONDENSED INDAN DERIVATIVES AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS | |
HUT66197A (en) | Composition based on alkyl polyglycosides which are usable for conditioning materials containing keratine, as well as using thereof for hair-washing and hair-conditioning | |
TR199801318T2 (en) | Acyclic nucleoside derivatives. | |
RU95119421A (en) | TRIORGANOSILANE DERIVATIVES OF BENZOTRIAZOLE CONTAINING THEIR COSMETIC COMPOSITIONS AND SKIN PROTECTION METHOD | |
AR015964A1 (en) | ISOQUINOLINE COMPOUNDS, ITS USE, PROCEDURE TO TREAT AN AFFECTION, COMPOUND PREPARATION PROCEDURE, PHARMACEUTICAL COMPOSITION THAT LOCONTIATES AND USEFUL COMPOUND IN THIS PROCEDURE | |
KR920002710A (en) | Anionic compound | |
RU95120189A (en) | NEW DI- OR THREE ORGANO-SILOXANES, SOLAR FILTERS AND CONTAINING THEIR PHOTO PROTECTIVE COSMETIC COMPOSITIONS ON THEIR BASIS | |
DE58905524D1 (en) | Organopolysiloxane thiourea derivatives, process for their preparation and use. | |
ES2059922T3 (en) | DERIVATIVES OF ORGANOPOLISILOXANO-TIOUREAS SUBSTITUTED WITH AMINO ALKYL, PROCEDURE FOR ITS PREPARATION AND EMPLOYMENT. | |
FI904171A0 (en) | Process for the preparation of 2'-deoxyuridine derivatives useful as drugs | |
FR2677023B1 (en) | WATER-SOLUBLE COUMARIN DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ENZYME SUBSTRATE. | |
NO910167L (en) | HAARFARGEMIDDEL. |